10-Q: Salarius Pharmaceuticals Merges with Decoy, Secures $6.3M

Salarius Pharmaceuticals completed its merger with Decoy Therapeutics, shifting focus to AI-driven peptide conjugates, and raised $6.3 million in a public offering, extending its cash runway to Q1 2027.

Summary

• Salarius Pharmaceuticals completed its merger with Decoy Therapeutics, Inc. on November 12, 2025, making Decoy a wholly-owned subsidiary.
• The combined entity will focus on Decoy's preclinical-stage pipeline of peptide conjugate drug candidates, leveraging machine learning and AI for infectious diseases and oncology.
• Salarius's existing asset, SP-3164, will be integrated into Decoy's platform to create peptide-based proteolysis targeting chimeras (P-PROTACs).
• The company successfully raised approximately $6.3 million in net proceeds from a public offering that closed on November 12, 2025, issuing common stock and various warrants.
• Cash and cash equivalents increased to $4.8 million as of September 30, 2025, from $2.4 million at December 31, 2024.
• Net loss for the nine months ended September 30, 2025, improved to $(3.54) million from $(4.11) million in the prior year period.
• Research and development expenses decreased to $253,741 for the nine months ended September 30, 2025, from $594,683 in the same period of 2024, primarily due to cost-savings.
• General and administrative expenses also decreased to $3.33 million for the nine months ended September 30, 2025, from $3.65 million in the prior year.
• The company regained compliance with Nasdaq's Minimum Bid Price Rule and Equity Standard, but remains under a one-year Mandatory Panel Monitor.
• New management appointments include Frederick E. Pierce as CEO, Dr. Barbara Hibner as Chief Scientific Officer, and Peter Marschel as Chief Business Officer, effective November 12, 2025.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the successful merger and significant capital raise, which extends the cash runway and diversifies the pipeline. However, the company remains preclinical, faces substantial dilution, and still carries a 'going concern' warning, tempering overall optimism.

Positives

• Completion of the merger with Decoy Therapeutics expands the company's pipeline into novel peptide conjugate therapeutics leveraging AI/ML.
• Successful public offering raised approximately $6.3 million in net proceeds, significantly bolstering liquidity.
• Cash and cash equivalents increased by approximately $2.37 million to $4.81 million as of September 30, 2025, compared to December 31, 2024.
• Net loss for the nine months ended September 30, 2025, decreased by $0.57 million compared to the same period in 2024, indicating improved operational efficiency.
• Research and development expenses decreased by $340,942 for the nine months ended September 30, 2025, reflecting cost-saving measures.
• General and administrative expenses decreased by $325,271 for the nine months ended September 30, 2025, also due to cost-saving initiatives.
• Regained compliance with Nasdaq's Minimum Bid Price Rule and Equity Standard, reducing immediate delisting concerns.
• The company believes its existing cash and cash equivalents, including proceeds from the November 2025 Offering, will fund operations through the first quarter of 2027.

Negatives

• The company has no products approved for commercial sale and has not generated any revenue from product sales to date.
• Suffered recurring losses from operations since inception, with an accumulated deficit of $85.5 million as of September 30, 2025.
• Substantial doubt exists regarding the company's ability to continue as a going concern without additional capital.
• The November 2025 Offering involved the issuance of common stock and various warrants, which will likely cause significant dilution to existing shareholders.
• The conversion of Series A and Series B Preferred Stock issued in the merger requires stockholder approval and Nasdaq initial listing approval, posing a potential hurdle.
• The conversion ratio for preferred stock was reset due to the dilutive financing, potentially increasing the number of common shares underlying preferred stock.
• The company is subject to a one-year Mandatory Panel Monitor by Nasdaq, meaning any future non-compliance with the Equity Standard or Bid Price Rule could lead to delisting without a compliance period.

Risks

• Nasdaq may delist securities if initial listing standards are not met or if compliance with monitoring conditions is breached.
• Decoy has never generated revenue from product sales, and all product candidates are in the preclinical stage, with no guarantee of successful development or commercialization.
• The company will continue to incur significant losses and requires substantial additional capital to fund operations beyond Q1 2027, which may not be available on acceptable terms or at all.
• Reliance on third-party alliance partners for financial, scientific, manufacturing, marketing, and sales resources for product candidates, with risks of non-performance or termination.
• The novel approach of using AI/ML in drug discovery is unproven and may not lead to marketable products, and the technology is subject to rapid changes and unique risks.
• Inability to obtain or protect intellectual property rights related to future products and product candidates could hinder competitive advantage.
• Potential for third-party intellectual property infringement claims, leading to substantial damages, royalties, or injunctions.
• Intense competition from major pharmaceutical and biotechnology companies with greater resources and more advanced pipelines.
• Cybersecurity threats and other security disruptions could compromise proprietary data, disrupt operations, and lead to significant costs or liabilities.
• Product candidates may cause adverse effects or have other properties that could delay or prevent regulatory approval or limit market acceptance.
• Changes in the U.S. presidency and federal government policies could lead to adverse regulatory developments, staff reductions at the FDA, or reduced federal grants.

Future Outlook

The company expects higher research and development and general and administrative expenses after the closing of the Decoy merger as it advances the clinical development of acquired assets and incorporates the Decoy business. It believes its current cash and cash equivalents, including proceeds from the recent public offering, will be sufficient to fund operations through the first quarter of 2027. However, substantial additional capital will be required for further product development and operations beyond this period, with no assurance of obtaining such funding on favorable terms or at all.

Management Comments

• "We believe that there is substantial doubt about our ability to continue our current and planned clinical programs for a period exceeding 12 months from the date of this filing with the SEC."
• "We will continue to require substantial additional capital to continue our operations and advance our clinical development activities and will need such additional capital to continue to fund our operations beyond the first quarter of 2027."
• "We believe the synergies between Decoy and Salarius are evident in our combined approach to drug development. Decoy's expertise in peptide conjugates complements Salarius' small molecule assets. This combination could enable us to address a wider range of diseases and potentially undruggable targets."
• "We plan to integrate Salarius assets, particularly the proprietary compound SP-3164, to expand our opportunities in creating a novel class of peptide conjugates called peptide-based proteolysis targeting chimeras (P-PROTACs)."

Industry Context

The merger positions Salarius (now with Decoy) in the rapidly evolving field of peptide conjugate therapeutics, a major drug modality exemplified by successful diabetes and weight loss treatments like Ozempic and Wegovy. Decoy's leverage of machine learning and artificial intelligence for drug design aligns with a growing trend in biotech to accelerate discovery and reduce development complexity. The focus on infectious diseases and oncology, particularly with novel mechanisms like P-PROTACs, places the company in highly competitive but potentially lucrative therapeutic areas. The industry faces high R&D costs, significant regulatory hurdles, and intense competition, making successful commercialization a low-probability event.

Comparison to Industry Standards

• The company's preclinical stage pipeline for peptide conjugates is typical for early-stage biotechnology companies, but the integration of AI/ML for drug design, similar to companies like Recursion Pharmaceuticals or BenevolentAI, represents an advanced approach to drug discovery.
• The high rate of drug development failure (e.g., 25-30% success rate from Phase 3 to Phase 4 as cited by the FDA) is a standard industry challenge that Decoy's pipeline will face.
• The need for substantial additional capital and the 'going concern' warning are common for pre-revenue biopharmaceutical companies, similar to many small-cap biotech firms that rely heavily on equity financing for R&D.
• The focus on peptide conjugates for respiratory viruses and GI cancers places Decoy in competition with established players and other emerging biotechs developing similar modalities, such as those working on GLP-1 agonists (e.g., Novo Nordisk, Eli Lilly) or novel antiviral therapies (e.g., Gilead Sciences, Merck).

Management Changes

Corporate Governance

Related Party Transactions

• On September 2, 2025, Salarius issued a promissory note (Note 1) to Decoy Therapeutics, Inc. in the principal amount of $200,000, bearing 0% interest, maturing November 17, 2025.
• On October 1, 2025, Salarius issued a promissory note (Note 2) to Decoy Therapeutics, Inc. in the principal amount of $100,000, bearing 0% interest, maturing November 17, 2025.
• On October 6, 2025, Salarius issued a promissory note (Note 3) to Decoy Therapeutics, Inc. in the principal amount of $270,000, bearing 0% interest, maturing November 17, 2025.

Stakeholder Impact

• **Shareholders**: Face significant dilution from the recent public offering and potential future dilution from the conversion of Series A and B Preferred Stock. The stock is subject to Nasdaq's Mandatory Panel Monitor, increasing delisting risk if compliance is not maintained. The merger and new pipeline offer potential long-term value but come with high development risks.
• **Employees**: Management changes occurred with new CEO, CSO, and CBO appointments, and the former CEO transitioning to EVP and CFO. A transaction bonus was approved for the former acting CEO.
• **Creditors**: Promissory notes issued to Decoy Therapeutics prior to the merger will be paid off using proceeds from the November 2025 Offering.
• **Customers/Patients**: The shift to Decoy's preclinical pipeline focusing on peptide conjugates for infectious diseases and oncology, and continued support for SP-2577, indicates a long-term commitment to developing new treatments, but no immediate impact as products are not commercialized.

Next Steps

• Advance the clinical development of the research and development programs acquired in the Decoy merger.
• Pay off certain outstanding promissory notes of Decoy Therapeutics, Inc. as required.
• Obtain stockholder approval for the conversion of Series A and Series B Preferred Stock into common stock.
• Obtain Nasdaq approval for the company's initial listing application post-merger.
• Continue supporting MDACC's ongoing investigator-initiated clinical trial evaluating seclidemstat (SP-2577) in combination with azacytidine for certain blood disorders.
• Conduct a thorough review of the seclidemstat small molecule program.
• Potentially seek additional capital through equity or debt instruments, or new collaborations/partnerships, to fund operations beyond Q1 2027.

Key Dates

Recommendation

The completion of the Decoy merger and the successful capital raise are positive developments, providing a new strategic direction and extending the company's cash runway. However, the company remains in the preclinical stage with no revenue, faces substantial dilution from recent financings, and carries a 'going concern' warning. The new pipeline, while promising with AI/ML integration, is high-risk and long-term. The Nasdaq compliance, while regained, is under a strict monitoring period. Given the significant risks inherent in early-stage biopharmaceutical development and the recent dilution, a 'hold' recommendation is appropriate for investors who are already exposed and believe in the long-term potential of the new pipeline, while new investors should exercise caution due to the speculative nature and high risk profile.

Keywords

Biopharmaceutical, Decoy Therapeutics, Merger, Peptide Conjugates, AI Drug Discovery, Oncology, Infectious Diseases, Preclinical Development, SEC Filing, 10-Q, Nasdaq Compliance, Capital Raise, Warrants, SP-3164, Seclidemstat